Prophylaxis of cytomegalovirus disease in high-risk patients.

被引：2
|
作者：
Scholz, M
Cinatl, J
Doerr, W
机构：
[1] Johann Wolfgang Goethe-Universität,Institut für Medizinische Virologie
来源：
INFECTION | 1997年 / 25卷 / 05期
关键词：
D O I：
10.1007/BF01720395
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
CMV disease is an important peristent factor for enhanced morbidity and mortality in immunocompromised patients. In high-risk patients the prevention of primary infection or reactivation of latent infection is endeavoured by means of various antiviral strategies. However, the prevention of CMV disease by immunomodulators appears to be a hopeful additional tool for the treatment of immunocompromised patients and ought to be further investigated.
引用
收藏
页码：269 / 273
页数：5
相关论文
共 50 条
  • [1] Prophylaxis of cytomegalovirus disease in high-risk patients
    M. Scholz
    J. Cinatl
    H. W. Doerr
    Infection, 1997, 25 : 269 - 273
  • [2] Use of venous thromboembolism prophylaxis in high-risk patients.
    Gelber, RP
    Chen, Y
    Seto, TB
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 : 283 - 283
  • [3] CYTOMEGALOVIRUS PROPHYLAXIS STRATEGIES IN HIGH-RISK TRANSPLANTATION
    SNYDMAN, DR
    TRANSPLANTATION PROCEEDINGS, 1994, 26 (05) : 20 - 22
  • [4] Economic Analysis of Extended Cytomegalovirus Prophylaxis in High Risk Kidney Transplant Patients.
    Luan, Fu Lung
    Stucky, Linda
    Park, Jeong M.
    Ojo, Akinlolu
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 250 - 250
  • [5] Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis
    Akalin, E
    Sehgal, V
    Ames, S
    Hossain, S
    Daly, L
    Barbara, M
    Bromberg, JS
    AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (06) : 731 - 735
  • [6] Failure of ganciclovir prophylaxis of primary cytomegalovirus disease in immunologic high-risk recipients
    Conti, DJ
    Isenberg, A
    Shen, GK
    Hahn, A
    Singh, TP
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) : 1314 - 1315
  • [7] Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: Is it effective?
    Goral, S
    Ynares, C
    Dummer, S
    Helderman, JH
    KIDNEY INTERNATIONAL, 1996, 50 : S62 - S65
  • [8] Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients
    Bodro, Marta
    Sabe, Nuria
    Llado, Laura
    Baliellas, Carme
    Niubo, Jordi
    Castellote, Jose
    Fabregat, Joan
    Rafecas, Antoni
    Carratala, Jordi
    LIVER TRANSPLANTATION, 2012, 18 (09) : 1093 - 1099
  • [9] Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients
    Golob, Stephanie
    Batra, Jaya
    DeFilippis, Ersilia M.
    Uriel, Matan
    Carey, Matt
    Gaine, Maureen
    Mabasa, Angelo
    Fried, Justin
    Raikelkar, Jayant
    Restaino, Susan
    Lee, Sun Hi
    Latif, Farhana
    Yuzefpolskaya, Melana
    Colombo, Paolo C.
    Choe, Jason
    Majure, David
    Jennings, Douglas
    Pereira, Marcus R.
    Clerkin, Kevin
    Sayer, Gabriel
    Uriel, Nir
    CLINICAL TRANSPLANTATION, 2022, 36 (12)
  • [10] The problem of cytomegalovirus (CMV) prophylaxis in high-risk renal transplant recipients
    Maiwald, J
    Sperschneider, H
    Stein, G
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (09) : 1897 - 1897
12345